References
- Akiyama, H. (2001). Antibacterial action of several tannins against Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 48(4), 487–491. https://doi.org/https://doi.org/10.1093/jac/48.4.487
- Androutsopoulos, V. P., Papakyriakou, A., Vourloumis, D., Tsatsakis, A. M., & Spandidos, D. A. (2010). Dietary flavonoids in cancer therapy and prevention: Substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacology & Therapeutics, 126(1), 9–20. https://doi.org/https://doi.org/10.1016/j.pharmthera.2010.01.009
- Balasuriya, B. N., & Rupasinghe, H. V. (2011). Plant flavonoids as angiotensin converting enzyme inhibitors in regulation of hypertension. Functional Foods in Health and Disease, 1(5), 172–188.
- Boussoualim, N., & Abderrahmane, B. (2011). Kinetic study of different flavonoids as inhibitors of beta-lactamase enzyme. African Journal of Biochemistry Research, 5(10), 321–327.
- Briongos‐Figuero, L. (2012). Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended‐spectrum beta‐lactamase (ESBL)‐producing enterobacteria. International Journal of Clinical Practice, 66(9), 891–896.
- Bush, K., & Bradford, P. A. (2016). β-Lactams and β-lactamase inhibitors: An overview. Cold Spring Harbor Perspectives in Medicine, 6(8), a025247. https://doi.org/https://doi.org/10.1101/cshperspect.a025247
- Bush, K., & Bradford, P. A. (2019). Interplay between β-lactamases and new β-lactamase inhibitors. Nature Reviews Microbiology, 17(5), 295–306. https://doi.org/https://doi.org/10.1038/s41579-019-0159-8
- Chikauchi, K. Metallo-β-lactamase inhibitors. (2012). Google Patents.
- Christian, N. A., Roye-Green, K., & Smikle, M. (2010). Molecular epidemiology of multidrug resistant extended spectrum beta-lactamase producing Klebsiella pneumoniae at a Jamaican hospital, 2000-2004. BMC Microbiology, 10(1), 27. https://doi.org/https://doi.org/10.1186/1471-2180-10-27
- Comakli, V. (2020). Screening inhibitory effects of selected flavonoids on human recombinant aldose reductase enzyme: In vitro and in silico study. Archives of Physiology and Biochemistry, 1–7.
- Coulton, S., & Francois, I. (1994). β-lactamases: Targets for drug design. Progress in Medicinal Chemistry, 31, 297–350.
- Cueva, C., Moreno-Arribas, M. V., Martín-Alvarez, P. J., Bills, G., Vicente, M. F., Basilio, A., Rivas, C. L., Requena, T., Rodríguez, J. M., & Bartolomé, B. (2010). Antimicrobial activity of phenolic acids against commensal, probiotic and pathogenic bacteria. Research in Microbiology, 161(5), 372–382. https://doi.org/https://doi.org/10.1016/j.resmic.2010.04.006
- Denny, B. J., Lambert, P. A., & West, P. W. (2002). The flavonoid galangin inhibits the L1 metallo-β-lactamase from Stenotrophomonas maltophilia. FEMS Microbiology Letters, 208(1), 21–24. https://doi.org/https://doi.org/10.1016/S0378-1097(01)00580-8
- Drawz, S. M., Papp-Wallace, K. M., & Bonomo, R. A. (2014). New β-lactamase inhibitors: A therapeutic renaissance in an MDR world. Antimicrobial Agents and Chemotherapy, 58(4), 1835–1846. https://doi.org/https://doi.org/10.1128/AAC.00826-13
- Elliott, A. J., Scheiber, S. A., Thomas, C., & Pardini, R. S. (1992). Inhibition of glutathione reductase by flavonoids: A structure-activity study. Biochemical Pharmacology, 44(8), 1603–1608. https://doi.org/https://doi.org/10.1016/0006-2952(92)90478-2
- Eumkeb, G., Sakdarat, S., & Siriwong, S. (2010). Reversing β-lactam antibiotic resistance of Staphylococcus aureus with galangin from Alpinia officinarum Hance and synergism with ceftazidime. Phytomedicine, 18(1), 40–45. https://doi.org/https://doi.org/10.1016/j.phymed.2010.09.003
- Gordon, E. M. Beta-lactamase inhibitors and uses thereof. (2018). Google Patents.
- Hanson, N. D., & Sanders, C. C. (1999). Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae. Current Pharmaceutical Design, 5(11), 881–894.
- Karsisiotis, A. I., Damblon, C. F., & Roberts, G. C. (2013). Solution structures of the Bacillus cereus metallo-β-lactamase BcII and its complex with the broad spectrum inhibitor R-thiomandelic acid. The Biochemical Journal, 456(3), 397–407. https://doi.org/https://doi.org/10.1042/BJ20131003
- Mandal, S. M., Dias, R. O., & Franco, O. L. (2017). Phenolic compounds in antimicrobial therapy. Journal of Medicinal Food, 20(10), 1031–1038. https://doi.org/https://doi.org/10.1089/jmf.2017.0017
- Neu, H. C. (1990). β-lactamases, β-lactamase inhibitors, and skin and skin-structure infections. Journal of the American Academy of Dermatology, 22(5 Pt 1), 896–904. https://doi.org/https://doi.org/10.1016/0190-9622(90)70121-W
- Öztürk, H., Ozkirimli, E., & Özgür, A. (2018). A novel methodology on distributed representations of proteins using their interacting ligands. Bioinformatics (Oxford, England), 34(13), i295–i303. https://doi.org/https://doi.org/10.1093/bioinformatics/bty287
- Peleg, A. Y., & Hooper, D. C. (2010). Hospital-acquired infections due to gram-negative bacteria. The New England Journal of Medicine, 362(19), 1804–1813. https://doi.org/https://doi.org/10.1056/NEJMra0904124
- Perez-Llarena, F. (1997). The bla gene of the cephamycin cluster of Streptomyces clavuligerus encodes a Class A beta-lactamase of low enzymatic activity. Journal of Bacteriology, 179(19), 6035–6040.
- Sánchez‐Maldonado, A., Schieber, A., & Gänzle, M. (2011). Structure-function relationships of the antibacterial activity of phenolic acids and their metabolism by lactic acid bacteria. Journal of Applied Microbiology, 111(5), 1176–1184. https://doi.org/https://doi.org/10.1111/j.1365-2672.2011.05141.x
- Seleem, D., Pardi, V., & Murata, R. M. (2017). Review of flavonoids: A diverse group of natural compounds with anti-Candida albicans activity in vitro. Archives of Oral Biology, 76, 76–83. https://doi.org/https://doi.org/10.1016/j.archoralbio.2016.08.030
- Shapiro, A. B., Gao, N., Jahić, H., Carter, N. M., Chen, A., & Miller, A. A. (2017). Reversibility of covalent, broad-spectrum serine β-lactamase inhibition by the diazabicyclooctenone ETX2514. ACS Infectious Diseases, 3(11), 833–844. https://doi.org/https://doi.org/10.1021/acsinfecdis.7b00113
- Siriwong, S., Teethaisong, Y., Thumanu, K., Dunkhunthod, B., & Eumkeb, G. (2016). The synergy and mode of action of quercetin plus amoxicillin against amoxicillin-resistant Staphylococcus epidermidis. BMC Pharmacology and Toxicology, 17(1), 1–14. https://doi.org/https://doi.org/10.1186/s40360-016-0083-8
- Stamm, W. (1999). The epidemiology of urinary tract infections: Risks factors reconsidered. In Interscience Conference on Antimicrobial Agents and Chemotherapy.
- Stapleton, P., Wu, P. J., King, A., Shannon, K., French, G., & Phillips, I. (1995). Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrobial Agents and Chemotherapy, 39(11), 2478–2483. https://doi.org/https://doi.org/10.1128/aac.39.11.2478
- Sykes, R., & Matthew, M. (1976). The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics . The Journal of Antimicrobial Chemotherapy, 2(2), 115–157. https://doi.org/https://doi.org/10.1093/jac/2.2.115
- Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/https://doi.org/10.1002/jcc.21334
- Wong, D., & Van Duin, D. (2017). Novel beta-lactamase inhibitors: Unlocking their potential in therapy. Drugs, 77(6), 615–628. https://doi.org/https://doi.org/10.1007/s40265-017-0725-1
- Zhao, W. H., Hu, Z. Q., Okubo, S., Hara, Y., & Shimamura, T. (2001). Mechanism of synergy between epigallocatechin gallate and beta-lactams against methicillin-resistant Staphylococcus aureus . Antimicrobial Agents and Chemotherapy, 45(6), 1737–1742. https://doi.org/https://doi.org/10.1128/AAC.45.6.1737-1742.2001